Package Leaflet: Information for the Patient
Emylif 50mg buccal film
riluzole
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
What is Emylif
The active substance of Emylif is riluzole, which acts on the nervous system.
What is Emylif used for
Emylif is used in adult patients with amyotrophic lateral sclerosis (ALS).
ALS is a type of motor neuron disease that affects the nerve cells responsible for sending signals to muscles, leading to weakness, muscle loss, and paralysis.
The destruction of nerve cells in motor neuron diseases may be due to an excess of glutamate (a chemical messenger) in the brain and spinal cord. Emylif stops the release of glutamate, which may help prevent damage to nerve cells.
Consult your doctor for more information about ALS and why this medication has been prescribed for you.
Do not take Emylif
Warnings and precautions
Consult your doctor before taking Emylif:
If you are in any of the above situations or are unsure, consult your doctor for advice on what to do.
Children and adolescents
The use of this medication is not recommended in children under 18 years of age, as there is no information available for this population.
Other medications and Emylif
Tell your doctor if you are taking, have recently taken, or may take any other medications.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, or think you may be pregnant, DO NOT take this medication.
If you are planning to become pregnant or breastfeed, consult your doctor before taking this medication.
Driving and using machines
You can drive and use all types of machines and tools, unless you experience dizziness or drowsiness after taking this medication.
Emylif contains:
Follow the administration instructions for this medication exactly as indicated by your doctor. If you are unsure, consult your doctor or pharmacist again.
The recommended dose is one buccal film twice a day.
The buccal film should be taken orally, every 12 hours, at the same time each day (e.g., morning and night).
After taking this medication, you may experience a decrease in oral sensitivity after 1 minute. Until this sensation disappears, which usually takes about 40 minutes, be cautious when consuming food.
Method of administration:
The following are the oral administration instructions.
Step 1. Before taking Emylif
Do nottake this medication if it has expired. | |
Figure 1 |
Step 2. Open the sachet
| |
Figure 2 |
Step 3. Remove the film
| |
Figure 3 |
Step 4. Place the film on your tongue
| |
Figure 4 |
Step 5. Close your mouth and swallow saliva normally
| |
Figure 5 | |
Step 6. After administering Emylif, wash your hands |
If you take more Emylif than you should
If you take too many buccal films, contact your doctor or go to the emergency department of the nearest hospital immediately.
If you forget to take Emylif
If you forget to take a buccal film, skip it and take the next one at the usual time.
Do not take a double dose to make up for the forgotten dose.
If you have any further questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
IMPORTANT
Tell your doctor immediately
Other side effects
Very common side effects(may affect more than 1 in 10 people) of this medication are:
Common side effects(may affect up to 1 in 10 people) of this medication are:
Uncommon side effects(may affect up to 1 in 100 people) of this medication are:
Side effect of unknown frequency(cannot be estimated from available data) of this medication is:
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Medicines Monitoring System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date stated on the sachet and carton after "EXP". The expiration date is the last day of the month indicated.
Store below 30°C.
Medications should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Composition of Emylif
polacrilin, pullulan (E1204), xylitol (E967), hypromellose (E464), glycerol (E422), glycerol monooleate, sucralose (E955), fructose, macrogol, honey flavor, xanthan gum, lemon flavor, orange yellow S (E110), white ink (purified water, titanium dioxide [E171], propylene glycol [E1520], hypromellose [E464], isopropyl alcohol, ethanol, and methanol).
Insufficient levels of the antioxidant butylated hydroxytoluene (E321).
Appearance of the product and pack contents
Buccal film:
Thin, rectangular, orange-colored buccal film (32 mm x 22 mm) with "R50" printed in white on one side.
Emylif is available in packs of 14, 28, 56, 98, 112, and 140 buccal films for oral administration.
Each carton contains 14, 28, 56, 98, 112, and 140 sachets.
Not all pack sizes may be marketed.
Marketing authorization holder
Zambon S.p.A.
Via Lillo del Duca 10
20091 Bresso (MI), Italy
Phone: +39 02665241
Fax: +39 02 66501492
Email: info.zambonspa@zambongroup.com
Manufacturer
Zambon S.p.A.
Via della Chimica, 9
36100 Vicenza
Italy
You can request more information about this medication from the local representative of the marketing authorization holder:
Zambon, S.A.U.
Maresme 5
Polígono Can Bernades - Subirà
08130 Santa Perpetua de Mogoda (Barcelona) Spain
Phone: +34 93 544 64 00
This medication is authorized in the EEA member states under the following names:
Emylif: Austria, Belgium, Denmark, Finland, France, Germany, Iceland, Italy, Luxembourg, Norway, Portugal, Spain, Sweden, Netherlands.
Date of last revision of this package leaflet: October 2022
Detailed information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS): http://www.aemps.gob.es/